# OnCo record blinatumomab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/blinatumomab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "blinatumomab" ;
  schema:name "Blinatumomab"@en ;
  schema:description "Blinatumomab was the first T-cell engager (2014), and is now given to children and adults with leukaemia even when in remission, because it improves survival."@en ;
  schema:url <https://onco.cc/drugs/blinatumomab/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Blinatumomab> ;
  owl:sameAs <http://www.wikidata.org/entity/Q410189> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Blinatumomab> ;
  onco:status "approved" ;
  onco:modality "Bispecific T-cell engager (CD19×CD3)" ;
  schema:alternateName "Blincyto" ;
  onco:approval "US 2014: Relapsed/refractory B-ALL", "US 2024: Consolidation in CD19+ B-ALL regardless of MRD" ;
  onco:acceleratedApproval "US 2014-12-03: Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia", "US 2018-03-29: Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1" ;
  onco:acceleratedApprovalConfirmed "US 2017-07-11: Philadelphia chromosome negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia", "US 2023-06-20: Treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children 1" ;
  onco:related <https://onco.cc/biomarkers/cd19-expression/> ;
  onco:cancers <https://onco.cc/cancers/all-leukemia/>, <https://onco.cc/cancers/all-paediatric-standard-risk/>, <https://onco.cc/cancers/all-paediatric-relapsed/>, <https://onco.cc/cancers/all-infant/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/cd3/> ;
  onco:companies <https://onco.cc/companies/amgen/> ;
  onco:trials <https://onco.cc/trials/nct04521231/>, <https://onco.cc/trials/nct07134088/>, <https://onco.cc/trials/nct07387926/> .